Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD)
Phase of Trial: Phase I/II
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Sobetirome (Primary)
- Indications Adrenoleucodystrophy
- Focus Adverse reactions
- Sponsors NeuroVia
- 26 Jul 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 May 2018 to 1 Aug 2018.
- 25 Jul 2018 According to a NeuroVia media release, this study has been initiated in Australia, Chile and the United Kingdom.
- 05 Jun 2018 Status changed from not yet recruiting to recruiting.